Endovascular treatment of abdominal aortic aneurysms.

OBJECTIVE: The purpose of this paper is to briefly review the historical aspects and outcome of endoluminal abdominal aortic aneurysm (AAA) repair and summarise two studies presented at the 1997 and 1998 meetings of the Society for Vascular Surgery. PATIENTS: Between May 1992 and September 1998 the endoluminal method was used to repair arterial aneurysms in 304 patients at the Royal Prince Alfred Hospital, Sydney, a tertiary referral teaching hospital. The study focuses on 243 patients with true AAA who underwent primary repair. There were 17 females and 226 males with a mean age of 72 years. Co-morbidities leading to rejection for conventional open repair were present in 83 patients. The criteria for inclusion included a segment of thrombus-free aorta between the lowermost renal artery and the commencement of the aneurysm of 1.5 cm or greater and iliac arteries that allowed access to the aorta from the groin. The technique involved the delivery of an endograft into the abdominal aorta by means of a sheath inserted through the femoral or iliac artery. Laparotomy associated with conventional open repair was avoided. Outcome measures included clinical examination and contrast-enhanced computed tomography (CT) within 10 days, at 6, 12, 18 months after operation and then annually thereafter. RESULTS: Endografts were successfully deployed in 226 patients. In the remaining 17 patients endoluminal repair was converted to open repair. There were 8 deaths within 30 days of operation giving a perioperative mortality rate of 3.3%. The two studies presented to the Society for Vascular Surgery concern: (i) a concurrent comparison of the endoluminal versus open methods of treating AAA; and (ii) a comparison of adverse events following endoluminal repair of AAA during two consecutive periods of time.     

Endovascular grafting of abdominal aortic aneurysms. A preliminary study.

OBJECTIVE: The authors report the experience of a single investigational center involving two Phase I and a Phase II clinical trials approved by the Food and Drug Administration (FDA) for the transfemoral implantation of woven Dacron grafts for abdominal aortic aneurysms. SUMMARY BACKGROUND DATA: In 1993, EndoVascular Technologies, Inc. ([EVT]; Menlo Park, CA), began an FDA-approved clinical trial of repair of abdominal aortic aneurysms by transfemoral placement of a tube endograft. Subsequently, a bifurcated endograft trial was started. This the first single institution report using the EVT endograft for both tube and bifurcated aortic replacement. METHODS: Seventeen patients were enrolled in two Phase I and one Phase II clinical trials. The Phase I tube graft trial and the Phase I bifurcated graft trial were nonrandomized studies. The Phase II tube graft trial consisted of a randomized prospective control trial of open endoaneurysmorrhaphy versus transfemoral placement of an endograft. RESULTS: Seventeen patients were enrolled in the trial. The graft was placed successfully in all but one patient. Five patients randomized to open procedure and one declined to participate. Eleven patients with endografts are available for follow-up. One graft has been explanted for attachment system migration. One patient is a late failure because of persistent filling of the aneurysm sac. CONCLUSION: Transfemoral placement of an endovascular graft is a viable and effective treatment of abdominal aortic aneurysms in the short term. Use of a bifurcated endograft will open the procedure to more patients. The ideal attachment system and graft material await long-term implantation follow-up.     

Endovascular treatment of abdominal aortic aneurysms

BACKGROUND: Endovascular treatment of abdominal aortic aneurysms is a rapidly evolving technique that has gained broad acceptance in the treatment of patients with abdominal aortic aneurysms. METHODS: A review of the English literature was done to determine the short- and long-term outcomes of endovascular repair of abdominal aortic aneurysms. Reports of complications such as endoleak, graft migration, graft limb occlusion, aneurysm rupture, and aneurysm enlargement were evaluated. RESULTS: Short-term results of endovascular repair of abdominal aortic aneurysms are excellent. The necessity for open conversions is less than 5%. The cumulative risk of aneurysm rupture is approximately 1% per year. The coverall incidence of graft limb occlusion was 2.8% in the follow-up period. The cumulative risk for a secondary procedure was 12% at 1 year, 24% at 2 years, and 35% at 3 years. Moderate and severe neck angulation was associated with an increased incidence of adverse events in the follow-up period. Endografts have the potential to become infected and develop aortoduodenal fistula. The treatment of ruptured aneurysms with endovascular grafts has been successful and a technique that is increasingly used. CONCLUSION: Endovascular treatment of abdominal aortic aneurysm is an effective technique with excellent short-term results. The long-term results remain to be determined. Ongoing surveillance is necessary to avoid late complications of aneurysm rupture.     

Endovascular treatment of abdominal aortic aneurysms

The management of abdominal aortic aneurysms has been revolutionized by the development of endovascular stent grafts. The deployment of these devices requires precise clinical and endovascular skills. This review aims to provide an overview of the essential aspects of an endovascular repair of an abdominal aortic aneurysm (EVAR), from initial presentation and assessment for the procedure through to follow-up and long-term outcomes. Consideration is also given to the newer devices, e.g. fenestrated and branched stent grafts, which have further expanded the numbers of patients who are suitable for treatment by EVAR. Abdominal aortic aneurysm etiology, screening and open repair is dealt with in the previous article.     

腔内人造血管移植术治疗腹主动脉瘤

目的 评价腔内人造血管移植术治疗腹主动脉瘤早期临床疗效。方法 总结对14例腹主动脉瘤患者采用经腹股沟切口腹主动脉瘤腔内人造管移植术的经验。结果 12例选用分叉型腔内人造血管,2例选用直型腔内人造人管,术后即刻DSA造影显示动脉瘤消失,近远端人造血管与宿主动脉结合处均未见渗漏,11例患者术后生命体征平稳,1例术后24h出现小面积急性心肌梗塞,经溶栓和抗凝治疗后缓解,术后死亡2例,技术成功率85.7%。12例患者术后1周随访螺旋CT,其中有4例术后3个月、1例术后12个月再次做螺旋CT,显示人造血管无移位,2例有渗漏,但动脉瘤腔无增大。结论 腔内人造血管移植术是一种创伤小、恢复快的治疗腹主动脉瘤新方法,但远期疗效有待随访。     

腹主动脉瘤的腔内修复治疗

腹主动脉瘤 (abdominalaorticaneurysms ,AAA)是血管外科常见的严重疾病 ,发病高峰年龄在 6 0～ 70岁之间 ,发病率男性是女性的 4～ 6倍 ,95 %的病例位于肾动脉平面以下。AAA最大的危险是瘤体破裂引起的致死性出血。通常认为 :瘤体 <5cm的AAA破裂发生率每年约 3% ;直径在 5～ 6cm的破裂发生率每年上升 10 %。一旦发生破裂 ,病死率高达 90 % ,手术死亡率 4 1%～ 70 % ,而择期手术死亡率仅 3%～ 5 %。因此只要无心、肺、肾功能不全等手术禁忌 ,本病均有手术适应证。最近的文献报告 ,AAA直径≥ 5 5cm是手术适应证[1] 。195 2年 ,Dubost[…     

Endovascular treatment of ruptured and symptomatic abdominal aortic aneurysms.

OBJECTIVE: To report the experience of endovascular repair (ER) in patients with ruptured and symptomatic abdominal aortic aneurysms (rAAA and sAAA), comparing results with a cohort of controls who underwent open repair (OR) of sAAA or rAAA. DESIGN: A historically controlled cohort study. MATERIALS: Retrospective data from 21 patients who underwent ER and prospective data from 23 patients who underwent OR. METHODS: Results were compared using the Mann-Whitney U-test. RESULTS: Eleven ER patients had sAAAs and 10 had rAAAs. Nine OR patients had rAAAs and 13 had sAAAs. Thirty-day mortality was 11% in patients with rAAA in the ER group, and 54% in the OR group (p=0.03). There were no post-operative deaths in the patients who had an sAAA in the ER group, and one death in the patients who had sAAA in the OR group. Results as expressed as mean ER value versus mean OR value and p-value. ER was associated with significant reductions in the length of operation (2.6 versus 3.1h, p=0.03), blood transfusion requirements (0.86 versus 10.7 units p<0.01), time in critical care (1.5 versus 6.1 days, p=0.02), and total hospital stay (8.5 versus 17.5 days, p=0.01) compared with OR. There was no difference in time from admission to arrival in theatre between the two groups (3.4 versus 5.0h, p=0.35). CONCLUSIONS: In patients with rAAA and sAAA that are suitable for stenting, ER has reduced mortality compared with open repair. Assessment for ER does not cause a pre-operative delay, operating time is reduced, blood transfusion requirements are reduced and there is a faster recovery.     

Endovascular stent graft selection for the treatment of abdominal aortic aneurysms

Minimally invasive endovascular techniques for the treatment of abdominal aortic aneurysms (AAA) have significantly reduced the morbidity of these procedures as compared with standard surgical repair. In addition, patients with extensive comorbid medical illnesses in whom standard operative repair is contra-indicated, may be successfully treated using endovascular means. A variety of endovascular stent grafts are currently being used clinically for endovascular AAA repair. The characteristics of these stent grafts vary significantly. In selecting the specific stent graft to be used for endovascular AAA repair, these specific characteristics must be considered particularly with regard to the individual patient's anatomic and physiologic characteristics. The United States Food and Drug Administration (FDA) has approved 4 endovascular stent grafts for the treatment of AAA: the Medtronic AneuRx, the W. L. Gore Excluder, the Cook Zenith and the Guidant Ancure. The Zenith graft received approval for marketing in 2003 and has gained relatively wide usage, in part due to its ability to treat aneurysms with relatively large diameter implantations zones. Also in 2003 the Guidant Corporation withdrew the Ancure graft from marketing and distribution. Enrollment has also been recently completed for the phase II FDA trials of the Medtronic Talent graft and the Cordis Fortron graft. These devices have been approved for use in the European Union and are awaiting FDA panel meeting in the United States. Comparative analysis of several of the available stent grafts has been performed. Results have varied with regard to the need for secondary interventions, aneurysm sac size reduction and the occurrence of continued perfusion of the aneurysm sac. Several significant advances have also occurred recently in stent graft research and development. Of particular significance has been the initiation of the phase I trial of the Trivascular Enovus graft. Deployment of the Trivascular graft may be accomplished through a delivery system that is considerably reduced in profile. The potential for percutaneous application of the graft may be available in the future. The indications for use of endovascular grafts as compared to standard open surgery have not yet been fully defined. Endovascular stent grafts in current use have limitations and their use must be tempered accordingly, until their long-term effectiveness is more completely evaluated. This article describes the general principles of use for endovascular devices for the repair of AAAs. It details the features and results for the devices in current use and highlights the factors that influence the selection of specific stent graft types.     

Endovascular stent grafting of aortic aneurysms

This contribution reviews the current status of stent grafting for abdominal aortic aneurysms.     

Endovascular treatment for para-anastomotic abdominal aortic and iliac aneurysms following aortic surgery

AIM: The aim of this study was to report our experience with endovascular repair of anastomotic aneurysms occurring after graft replacement for abdominal aortic aneurysms or aorto-iliac obstructive disease. METHODS: Between January 2000 and April 2006, 19 consecutive male patients (median age 73 years) underwent endovascular repair for 22 anastomotic aneurysms [proximal aortic (n=15), iliac (n=4), concomitant aortic and iliac (n=3)], occurring 3 months to 18 years (mean 8.6 years) after open surgery. Three patients (15.7%) underwent emergency treatment for rupture. No patient had symptoms or positive blood tests for infection of the original graft. Twelve patients were treated with a bifurcated stent-graft, 4 patients with a proximal stent-graft cuff, 2 patients with a tube iliac stent-graft, and 1 patient with a mono-iliac stent-graft. RESULTS: Stent-grafts were successfully deployed in all patients. Procedure-related complications or death were not observed; open conversion was never required. Median hospitalisation was 9 days (range 3-45). During a median follow-up of 16 Euro-months (range, 2-44) all anastomotic aneurysms maintained excluded: 4 patients (21%) died. We observed 1 major complication (5.2%): an iliac branch occlusion occurred 1 month after the procedure, successfully treated with catheter-directed thrombolysis. Overall, survival rates at 6, 12, 18 and 36-months were 92.8%, 84.4%, 72.3%, and 57.8% respectively. CONCLUSION: Our experience confirms that endovascular stent-grafts can be used successfully to exclude anastomotic aortic aneurysms after open surgery. Endovascular repair seems to be effective at mid-term follow-up.     

Endovascular management of abdominal aortic aneurysms

An estimated 1.5 million people in the United States have abdominal aortic aneurysms (AAAs) with more than 200000 American diagnosed each year. The natural history of AAAs is to expand and rupture, accounting for an estimated 15000 deaths per year. Thus, the major impetus for AAA repair is for prophylaxis against aneurysm-related death. The standard open surgical repair of AAAs is a well-established and durable procedure. However, as with all other major abdominal surgical operations, associated significant morbidity and mortality exist, along with prolonged recovery and various late complications. Furthermore, both mortality and morbidity increase significantly with advanced patient age and associated co-morbid disease states. Endovascular AAA repair using covered stent-grafts offers a significantly less invasive alternative to conventional open-surgical repair. A considerable reduction in hospital stay has been demonstrated, with early return to preoperative levels of activity. Patients previously considered unsuitable for open repair can often receive treatment for aneurysms with endovascular techniques. Current estimates are that more than 1/2 all infrarenal AAAs will be repaired using endovascular approach in the future. Despite the minimally-invasiveness of this new treatment, there are unanswered questions as to the durability and efficacy of devices, which results in concerns about their ability to successfully protect the patient from subsequent rupture. Three devices are commercially available and have been extensively used for implantation in the United States with a 4th device recently receiving approval from the Food and Drug Administration (FDA). In this review article, endovascular management of AAAs with these devices is described, as are the design and deployment techniques of the currently available endografts.     

腔内隔绝术微创治疗肾下腹主动脉瘤

我科2003年6月至12月应用微创人造血管腔内隔绝术（endovascular graft exclusion，EVGE）治疗肾下腹主动脉瘤（abdominal aortic aneurysms，AAA）4例，现报道如下。     

Endovascular treatment of aortic arch aneurysms.

INTRODUCTION: The aim of this study was to review our clinical experience with endovascular treatment of aortic arch aneurysms using different commercially available grafts (Gore, Talent, Endomed, Cook). METHODS: From 1999 to 2004, 97 patients received endovascular treatment for diseases of the thoracic aorta. In 30 cases (26 males, 4 females) the aortic arch was involved. The left subclavian artery was overstented (Ishimaru zone '2') in 18 cases (60%). Only in the first three cases had the subclavian artery been revascularized. The left common and subclavian arteries were covered (zone '1') in 6 (20%) cases-all had the carotid artery reconstructed, either simultaneously (five cases) or as a staged procedure (one case). Finally, the whole aortic arch was over-stented (zone '0') in 6 (20%) cases, with simultaneous (five cases) or staged (one case) grafting of the supra-aortic vessels from the ascending aorta. RESULTS: Perioperative mortality was 2/30 (7%), due to graft migration (zone '2') and intra-operative stroke (zone '0'), respectively. One minor stroke was observed. No cases of paraplegia were recorded. Three type I endoleaks were observed. Two resolved at 6 months follow-up; one zone '0' graft is still being followed. There was one surgical conversion for endograft failure 2 weeks after implantation. Thus, the technical success rate was 87% (26/30) cases. The mean follow-up time was 23+/-17 months. No new onset endoleaks or aneurysm-related deaths were recorded. CONCLUSIONS: Currently available grafts may be deployed in the aortic arch in most instances. De-branching of the aortic arch with surgical revascularization for zone '0' and '1' seems to be adequate to obtain a satisfactory proximal landing zone.     

Endovascular grafting for abdominal aortic aneurysms: Changing incidence and indications for conversion to open operation

The incidence and indications for conversion from endoluminal to open repair of abdominal aortic aneurysms are changing. This paper is based on a 5-year experience in which endoluminal repair of abdominal aortic aneurysms was undertaken in 156 patients. Primary conversion at the original operation was required in 14 patients and secondary conversion at a subsequent operation was required in 9 patients. The reasons for primary conversion were access problems (n = 2), balloon related problems (n = 2), endograft migration (n = 4), endograft thrombosis (n = 1) and failed deployment of a bifurcated endograft (n = 5). Twelve of 14 primary conversions occurred in the first half of the study period, in which 59 endoluminal abdominal aortic aneurysms repairs were undertaken. Improvements in technology and interventional techniques for overcoming obstacles, as well as increasing experience, has resulted in primary conversion being limited to two patients in the most recent 2.5-year period in which 97 endoluminal repairs were undertaken. The reasons for secondary conversion were renal arteries covered by the endograft (n = 2), increasing abdominal aortic aneurysm diameter in the absence of endoleak (n = 1) and persistent endoleak (n = 6). The latter group comprised three patients with intact aneurysms and three with known endoleaks who presented with ruptured aneurysms. The current indications for primary conversion include: (i) rupture of the aorta; (ii) complete migration of the endograft resulting in obstruction of the iliac arteries; and (iii) irreversible twisting of a non-modular bifurcated endograft. The current indications for secondary conversion include: (i) persistent endoleak; (ii) sealed endoleak with continued abdominal aortic aneurysms expansion; (iii) apparently successful endoluminal repair without evidence of endoleak but continued abdominal aortic aneurysms expansion; and (iv) infected endograft.     

复杂性腹主动脉瘤腔内治疗:问题与对策

目的探讨人工覆膜支架腔内修复术(EVAR)治疗复杂性腹主动脉瘤(AAA)的可行性与安全性。方法回顾性分析35例接受EVAR治疗的复杂性AAA的患者资料。结果 35例均接受EVAR治疗,2例失败(1例入路血管严重狭窄,支架不能释放,2天后死亡;1例术中瘤体破裂,手术中断,术后1天死亡),手术成功率为94.29%(33/35)。6例术前瘤体已破裂,术后死亡2例。结论对于复杂性AAA,通过改良技术进行腔内治疗,能够取得良好疗效。     

Endovascular treatment of thoracic aortic aneurysms

Endovascular repair of thoracic aortic aneurysms is a promising modality that may someday replace open surgical repair. While stent grafts have been used with moderate success in small to moderate-sized retrospective series, there have been no completed multicenter clinical trials directed at gaining approval from the U.S. Food and Drug Administration. The available data suggest that morbidity and mortality of the procedure may be lowered with endovascular techniques. Paraplegia occurs, but despite the inability to maintain perfusion of intercostal vessels, the rate is at least as low as that associated with open repair. Similar to the minimally invasive repair of infrarenal aneurysms, the trade-off between the open and endovascular approach rests in the necessity to follow patients closely with after endovascular repair. The long-term durability of available devices is unproved, and serial imaging studies must be followed in order to detect device failure prior to the development of devastating clinical sequelae.